These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Oder E; Safo MK; Abdulmalik O; Kato GJ Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087 [TBL] [Abstract][Full Text] [Related]
13. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents. Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Safo MK; Kato GJ Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263 [TBL] [Abstract][Full Text] [Related]
15. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia. Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381 [TBL] [Abstract][Full Text] [Related]
16. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells. Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905 [TBL] [Abstract][Full Text] [Related]
17. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities. Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397 [TBL] [Abstract][Full Text] [Related]
18. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Iyamu EW; Turner EA; Asakura T Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171 [TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease. Huang B; Ghatge MS; Donkor AK; Musayev FN; Deshpande TM; Al-Awadh M; Alhashimi RT; Zhu H; Omar AM; Telen MJ; Zhang Y; McMahon TJ; Abdulmalik O; Safo MK Molecules; 2022 Oct; 27(20):. PubMed ID: 36296435 [TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin. Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]